Halethazole has been studied as an active antifungal compound.

Halopemide is a new psychotropic agent, a structural analog of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings indicate that halopemide lacks the ability to induce parkinsonism and may be an effective drug in the treatment of psychosis characterized by autism, emotional withdrawal or apathy. However, the results from of the double-blind study showed no significant difference between the placebo phase and halopemide phase. Halopemide is phospholipase D2 inhibitor: PLD1 and PLD2. Halopemide may be used as a screen to identify inhibitors of human PLD2 using an in vitro biochemical assay. It is also inhibitory at benzodiazepine binding sites.

Datelliptium is a DNA-intercalating agent, an analog of a natural alkaloid ellipticine. The compound was active in vivo against a variety of murine solid tumors. In a phase I clinical trial no objective complete or partial responses were observed in patients with solid tumors or lymphoma treated with datelliptium.

Cyclopyrronium bromide is an anticholinergic agent, discovered by Robins Company, Inc. Ex vivo study has demonstrated that the compound was effective in inhibiting gastrointestinal motility in isolated guinea pig ileum.

Nonathymulin (Thymulin, FTS) is well defined nonapeptide hormone produced by thymic epithelial cells. Its biological activity and antigenicity depend upon the presence of the metal zinc in the molecule. Thymulin consists of a biologically inactive nonapeptide component termed FTS (anacronym for serum thymus factor in French) coupled in an equimolecular ratio to the ion zinc, which confers biological activity to the molecule. This pharmacologically active metallopeptide induces the differentiation of T-cells and enhances several functions of the various T-cell subsets in normal or partially thymus-deficient recipients. The peptide is a natural hormone, available in synthetic form. Thymulin has a selective immunomodulatory effect, enhancing anti-inflammatory and inhibiting pro-inflammatory cytokines. It suppresses p38 (implicated in glucocorticoid-resistance) and inhibits NF-kappaB activation, which has an important pathogenic role in several lung diseases. The broad spectrum of anti-inflammatory effects of this peptide in several animal models of lung disease makes thymulin a good candidate for future clinical trials. Thymulin was being investigated by Santen Pharmaceutical in Japan. Its development for the treatment of ischaemic heart disorders and rheumatoid arthritis in Japan was discontinued. Thymulin is probably the best characterized of all putative thymic hormones and seems to playa physiological role in thymus–pituitary communication, particularly during perinatal life. Interest in the therapeutic use of thymulin flourished during the 1970s and 1980s when efforts were almost exclusively focused on using thymulin for the treatment of autoimmune and other immunopathologies as well as cancer. Subsequent studies established that thymulin is active on the hypophysis and the brain. This awareness and the availability of a synthetic gene for metFTS have opened new avenues for the exploration and eventual exploitation of the therapeutic potential of this metallopeptide.

Clofilium is a quaternary ammonium compound that acts as potassium channel blocker. Clofilium is a class III agent. Clofilium increases atrial and ventricular effective refractory period without changing conduction time and, despite no apparent change in premature ventricular complex frequency, it can abolish the ability to induce ventricular tachycardia by programmed stimulation and is also well tolerated.

Norbudrine (KWD2109) is a sympathomimetic drug. It is an active bronchospasmolytic agent. KWD2109 shows an in vitro bronchospasmolytic acitivity which is about 14 times better than that of KWD2025. In the in vivo tests or guinea pig bronchospasmolytic activity KWD2109 has an effect which is about 3 times that of KWD2025 after intraperitoneal and oral administration

3-Aminopropionitrile (beta-aminopropionitrile, BAPN) is a poisonous substance found in Lathyrus spp. (wild peas), for example, Lathyrus hirsutus (wild winter pea), sometimes sown with grasses to provide early-spring grazing. BAPN is a specific and irreversible inhibitor of LOX activity. It has been shown to reduce body weight gain and improve the metabolic profile in diet-induced obesity in rats. The administration of beta-aminopropionitrile has been proposed for pharmacological control of unwanted scar tissue in human beings. BAPN has been shown to have preventive effect in the development of fibrosis by decreasing tissue damage in an experimental model of corrosive esophagitis in rats. BAPN is FDA approved for the treatment of tendinitis of the superficial digital flexor tendon (SDFT) in horses where there is sonographic evidence of fiber tearing.

Tyramine is a naturally occurring monoamine compound and trace amine derived from the amino acid tyrosine. Tyramine occurs widely in plants and animals, and is metabolized by the enzyme monoamine oxidase. Tyramine is an alpha-adrenergic agonist. Hypertension can occur, from ingestion of tyramine-rich foods in conjunction with monoamine oxidase inhibitors. The possibility that tyramine acts directly as a neurotransmitter was revealed by the discovery of a G protein-coupled receptor with high affinity for tyramine, called TAAR. It exhibits sympathomimetic effects by causing the release of endogenic norepinephrine. It has been used in mydriatic eyedrops. This has been said to reduce the intraocular pressure in rabbits and in some patients with open-angle glaucoma.

Deterenol is a beta-adrenoceptor agonist. It is an effective nonmydriatic and nonmiotic hypotensive agent, which can be used in antiglaucoma treatment.